22 February 2021
Visiongain has published a new report on Anti-snoring Treatment Market Report to 2031. According to the Visiongain analysis, the global Anti-Snoring Treatment market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Anti-Snoring Treatment market is segmented by devices, by surgery, and by end- users. By devices, the market is categorized as (Mandibular Advancement devices, Nasal Devices, Continuous Positive Airway Devices, Others), By Surgery (Radiofrequency Palatoplasty, Uvulopalatopharyngoplasty (UPPP), Tonsillectomy, Laser-assisted Uvulopalatoplasty, Others) By End User (Hospitals, Retail Pharmacies, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Anti-Snoring Treatment Companies. PLUS COVID-19 Recovery Scenarios.
Global Anti-Snoring Treatment Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The advancement of anti-snoring devices and increasing prevalence of sleeping disorder are some of the factors driving the growth of the global anti-snoring treatment market.
COVID-19 Impact on the Global Anti-Snoring Treatment Market
The COVID-19 pandemic has hugely affected the global anti-snoring market due to series of lockdown and social distancing rules. In response to the COVID-19, the lockdown was initiated as a safety measure, implemented with isolation, social distancing, and quarantine. This will likely reduce community transmission; however, it is huge challenge for the sleep apnea patients. The OSA patients have high risk of hospitalization due to the COVID-19 outcome.
Advancement of anti-snoring devices.
Snoring occurs when the tongue and tissues of the mouth and throat become too relaxed, the air passing through develops vibrations in the tissue, and creates high snoring sound, due to which most of the people lose sleep. Snoring can be highly disruptive and may indicate obstructive sleep apnea (OSA) or more serious medical condition. The advanced anti-snoring devices are designed such as Mandibular advancement devices, Tongue stabilizing devices, among others.
Increasing Smoking and Alcohol Consumption
Obstructive sleep apnea (OSA) is a disorder, which is characterized by partial or complete upper airway collapse results in apnea during sleep. According to the National Institute of Health the prevalence of OSA in the USA has been estimated at around 15% in men and 5% in women aged between 30–70 years. OSA is common among people who consume alcohol, and smokes, as consumption of alcohol possibly increases upper airway collapsibility and contribute to a higher body mass index. The alcohol consumption and smoking among people are at high risk associated with snoring and contribute towards anti-snoring treatment market
Increasing awareness about sleep apnea and treatment
According to the American Sleep Apnea Association, nearly 22 million Americans suffers from Sleep apnea. The untreated apnea results in serious health consequences, however, in recent years the awareness among people is increasing for sleep apnea, and the availability of devices are one of the factors boosting the anti-snoring treatment market globally.
Apnea Sciences Corporation, Medtronic Plc, ASF Medical GmbH (Tomed GmbH), Fisher & Paykel Healthcare Limited, Koninklijke Philips NV, Meditas Ltd., Whole You Inc., ResMed Corp., SomnoMed Limited, The Pure Sleep Company are some of the key players contributing to the growth of the global anti-snoring treatment market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
For instance, in March 2019, Apnea Sciences Corporation Launched SnoreRx at Walgreens Apnea Sciences. The US FDA cleared SnoreRx as an oral appliance for OTC treatment, which will be available at CVS pharmacies without a prescription.
In April 2019, ResMed launched AirFit P30i, its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option. The AirFit30i provides easy movement and enables home medical equipment (HME) providers to fit patients easier and faster.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.